SCHEMBL1968361

SCHEMBL1968361

CCOC(=O)c1nc(CC)sc1NC(=O)Oc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
MAPT P10636 4/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 2/20 0.47
PKM P14618 1/20 0.47
HSD17B10 Q99714 3/20 0.46
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
POLB P06746 2/20 0.44
MIF P14174 1/20 0.44
HPGD P15428 2/20 0.43
ILK Q13418 1/20 0.43
THRB P10828 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
CNR2 P34972 1/20 0.42
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1969591 0.91 ALDH1A1 (0.46) ALDH1A1MAPTRAB9ANPC1PKM
SCHEMBL27191915 0.85 TRPM8 (0.52) ALDH1A1MAPTRAB9ANPC1PKM
SCHEMBL4955898 0.81 ALDH1A1 (0.61) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL30216371 0.79 ILK (0.66) ALDH1A1MAPTRAB9ANPC1PKM
SCHEMBL4960060 0.78 CTSA (0.47) ALDH1A1MAPTRAB9ANPC1MEN1
SCHEMBL1968562 0.77 MAPK1 (0.52) ALDH1A1MAPTNPC1MEN1KMT2A
SCHEMBL16311044 0.77 KMT2A (0.58) ALDH1A1MAPTNPC1PKMHSD17B10
SCHEMBL22658875 0.76 ALDH1A1 (0.45) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL10760954 0.75 MAPT (0.60) ALDH1A1MAPTRAB9ANPC1HSD17B10
SCHEMBL4961091 0.75 TRPM8 (0.46) ALDH1A1MAPTRAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 ALDH1A1 279/4885MAPT 4280/4885RAB9A 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.